Palisade Bio Inc. receives Investment Bank Analyst Rating Update
Investing.com – U.S. stocks were lower after the close on Thursday, as losses in the Oil & Gas, Basic Materials and Technology sectors led shares lower. At the close in NYSE, the...
Investing.com – U.S. stocks were higher after the close on Friday, as gains in the Telecoms, Utilities and Technology sectors led shares higher. At the close in NYSE, the Dow...
Although it seems that investors have lost their appetite for many stem cell investments at this stage of the broader rally in the stock market, there are exceptions worth pointing...
Palisade Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing oral therapies that target diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal (GI) tract. Its lead therapeutic candidate, LB1148, is an oral liquid formulation of the digestive enzyme inhibitor, tranexamic acid, intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from, among other things, reduced blood flow to the intestine, infections, or due to surgery. Its LB1148 has been advanced to Phase III clinical trials for the return of bowel function indication, which is a protease inhibitor that helps to restore bowel function and reduce abdominal adhesions following surgery.
|Average||4.000 (+3408.77% Upside)|
|No. of Analysts||2|